Radiopharmaceutical Theranostics Market to Reach $4.9 Billion by 2028, Driven by Clinical Research and Nuclear Medicine Progress

The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $2.51 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to radiopharmaceutical development, clinical research advances, investment in research, regulatory approval, nuclear medicine progress.

The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $4.9 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to biomarker discovery and validation, genomic and proteomic technologies, precision radiotherapy development, interdisciplinary collaborations, patient advocacy and support. Major trends in the forecast period include ethical and legal considerations, telemedicine in theranostics,patient-centric care, radiopharmaceutical customization, nano-theranostics development.

Market Overview -
Radiopharmaceutical theranostics refers to a combined approach in medicine that combines therapeutics (treatment) and diagnostics (diagnosis) using radiopharmaceuticals. These are used for patient diagnosis, therapy, and personalized management.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp

The Surge In Cancer Incidence Boosts Radiopharmaceutical Theranostics Market Growth
The rising incidence of cancer is expected to propel the growth of the radiopharmaceutical theranostics market going forward. Cancer refers to a disease or condition of complex and abnormal growth of cells that can invade and spread to other parts of the body. Radiopharmaceutical theranostics helps in cancer treatment by providing targeted and personalized approaches. For instance, in 2023, according to the American Cancer Society, a US-based voluntary cancer health organization, in the US, 1.9 million new cancer cases are estimated to be diagnosed and about 609,820 deaths may occur due to cancer. Further, 88% of the people diagnosed are expected to belong to the 50 years or above age group. Therefore, the rising incidence of cancer is driving the growth of the radiopharmaceutical theranostics market.

Competitive Landscape -
Major companies operating in the radiopharmaceutical theranostics market report are Cardinal Health Inc., AstraZeneca Plc, GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

Technological Advancements Propel Radiopharmaceutical Theranostics Market Growth
Technological advancements are a key trend gaining popularity in the radiopharmaceutical theranostics market. Major companies operating in the radiopharmaceutical theranostics market are developing advanced technologies to sustain their position in the market. For instance, in March 2021, GE HealthCare Technologies Inc., a US-based medical technology company, launched StarGuide, its latest SPECT/CT technology, aimed at helping advance precision health and theranostics. This advanced system incorporates the latest Cadmium Zinc Telluride (CZT) technology, which enables healthcare providers to gain deeper insights into patient conditions and improve patient outcomes across various care areas. With its digital focus detectors and 360-degree imaging, StarGuide is expected to bolster precision health and enhance theranostics capabilities in nuclear medicine.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report

Key Segments -
The radiopharmaceutical theranostics market covered in this report is segmented -
1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers
2) By Source: Nuclear Reactors, Cyclotrons
3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes
4) By Indication: Oncology, Cardiology, Neurology, Other Indications
5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.